Trial reportPsychopharmacology2008
Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls.
Trial report in Psychopharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- The effect of glycine administration on the characteristics of physiological systems in human adults: A systematic review.GeroScience · 2024Pooled it
- Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.CNS drugs · 2011Pooled it
- Acute subanesthetic ketamine-induced effects on the mismatch negativity and their relationship to early and sustained treatment response in major depressive disorder.Journal of psychopharmacology (Oxford, England) · 2025Trial
- Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants.Psychopharmacology · 2010Trial
- Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study.Schizophrenia (Heidelberg, Germany) · 2022Article
- Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia.Frontiers in neuroscience · 2021Review
- NMDA Receptor Antagonist Effects on Speech-Related Mismatch Negativity and Its Underlying Oscillatory and Source Activity in Healthy Humans.Frontiers in pharmacology · 2019Article
- Toxicity of flavor enhancers to the oriental fruit fly, Bactrocera dorsalis (Hendel) (Diptera: Tephritidae).Ecotoxicology (London, England) · 2018Article
- Reorganisation of brain networks in frontotemporal dementia and progressive supranuclear palsy.NeuroImage. Clinical · 2013Article
- Glycine attenuates myocardial ischemia-reperfusion injury by inhibiting myocardial apoptosis in rats.Journal of biomedical research · 2012Article
- Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischaemia-reperfusion injury: current knowledge.British journal of pharmacology · 2012Review
- Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study.Psychopharmacology · 2012Article
- How human electrophysiology informs psychopharmacology: from bottom-up driven processing to top-down control.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Review
- Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate.Behavioural brain research · 2009Article
- The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice.Psychopharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSchizophrenia is commonly associated with impairments in pre-attentive change detection as represented by reduced mismatch negativity (MMN). The neurochemical basis of MMN has been linked to N-methyl-D: -aspartate (NMDA) receptor function. Glycine augments NMDA receptor function via stimulation of the glycine modulatory site of the NMDA receptor and has been shown to effectively reduce negative symptoms in schizophrenia. However, no study has investigated the possible effects of high-dose glycine on MMN. Further, the physiological consequences of administering high-dose glycine in subjects with normal NMDA receptor function are unknown.
objectivesThe aim of the present project was to investigate the acute effects of a single large dose of glycine on the human MMN in healthy subjects. MATERIALS AND
methodsSixteen healthy male subjects participated in a double blind, placebo-controlled, crossover design in which each subject was tested under two acute treatment conditions separated by a 1-week washout period; placebo and 0.8 g/kg glycine. The subjects were exposed to a duration-MMN paradigm with 50-ms standard tones (91%) and 100-ms deviant tones (9%).
resultsThe results showed that glycine significantly attenuated duration MMN amplitude at frontal electrodes. There was no effect of glycine on MMN latencies or on amplitudes or latencies of N1, N2 and P3a.
conclusionsThese findings suggest that an acute high dosage of glycine attenuates MMN in healthy controls, raising the possibility that optimal effects of glycine and other glycine agonists may depend on the integrity of the NMDA receptor system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.